Elicio Therapeutics (ELTX) Notes Payables (2020 - 2021)
Elicio Therapeutics' (ELTX) quarterly Notes Payables came in at $895000.0 in Q1 2021, up 244.23% on a QoQ basis from $260000.0 in Q4 2020.
Elicio Therapeutics (ELTX) Notes Payables (2020 - 2021) Analysis & Trends
Elicio Therapeutics (ELTX) has 2 years of Notes Payables data on file, last reported at $895000.0 in Q1 2021.
- Quarterly Notes Payables changed N/A year-over-year to $895000.0 in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $895000.0 (changed N/A YoY) and the FY2020 annual result came in at $260000.0, changed N/A from the prior year.
- Notes Payables advanced to $895000.0 in Q1 2021, from $260000.0 in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $895000.0 in Q1 2021 to a low of $260000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Elicio Therapeutics | 58.41 Mn | 34.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 895,000.00 |
| Dec 31, 2020 | 260,000.00 |